Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

Saved in:
Bibliographic Details
Main Authors: Remy S. Petersen, MD, Lauré M. Fijen, MD, PhD, Laurens E. Franssen, MD, PhD, Josephine M.I. Vos, MD, PhD, Danny M. Cohn, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Acquired C1-inhibitor deficiency
angioedema
monoclonal gammopathy
MGUS
daratumumab
bradykinin
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829324001188
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items